Oramed Pharmaceuticals Inc.

sinkt weiter

http://www.nasdaq.com/symbol/ormp/short-interest

 

http://www.youtube.com/watch?v=u7DId8IxJi4

 

Oramed Remains Strong With Near and Long-Term Catalysts

https://www.gurufocus.com/news/531649/...-near-and-longterm-catalysts

 

Es hilft alles nichts, weiter warten.
Trotzdem hoffe ich dass die nächsten Monate mal sichtbare Ergebnisse zeigen und der Kurs nachhaltig nach oben dreht ...

Solange chill and Grill  

Hoffe auf baldige News

https://clinicaltrials.gov/ct2/show/NCT02535715?term=oramed&rank=1  

sollen laut Quartalsbericht im Februar bis Ende Juni kommen:

In February 2017  ,  we completed a Phase IIa dose finding clinical trial which was initiated in October 2016. This randomized, double-blind trial was conducted on 32 type 2 adult diabetic patients in order to define the optimal dosing of ORMD-0801 moving forward  . We anticipate receiving the clinical study report in the second quarter of calendar year 2017.

In March 2017, we initiated a six month toxicology study for use of our oral insulin capsule for a longer period than previously performed, as preparation for our future Phase III study. We anticipate receiving the results in the third quarter of calendar year 2017.

In September 2013, we submitted a pre-IND package to the FDA for ORMD-0901, our oral exenatide capsule, for a Phase II clinical trial on healthy volunteers and type 2 diabetic patients. In      August 2015, we began a non-FDA approved clinical trial on type 2 diabetic patients. The trial was completed during the second quarter of calendar year 2016 and indicated positive results as it showed ORMD-0901 to be safe and well tolerated and also demonstrated encouraging efficacy data  . We completed a toxicology study in March 2017 and  anticipate receiving the results during the second quarter of calendar year 2017 and  expect to file an IND and move directly into a pharmacokinetics study followed by a large Phase II trial in the United States.  

Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule

http://www.nasdaq.com/press-release/...-analog-capsule-20170627-00578

 

Normal liefert Oramed immer sauber ab, ich hoffe die Tage kommt da noch was.

Als vorwärts!  

müsste zumindest Ende der Woche kommen.

Diesmal ist das Datum in der "Corporate Presentation" noch nicht dem neuen Monat angepasst worden. Ein Zeichen auf ein update?  

Gab es eine Art von Bonus oder warum hat das ganze Management Buy  Optionen bekommen?  

 

http://secfilings.nasdaq.com/...0INC.&FormType=10-Q&View=html

 

wird auch demnächst angepasst. Derzeit:

 

 

bereits bekannt!? Eine News ist mir dazu nicht bekannt.  

Da sollte noch die ein oder andere News in den Startlöchern stehen.
31. August Meeting mit der FDA wegen Phase 3, auch nicht schlecht!  

http://www.nasdaq.com/symbol/ormp/press-releases

11.07.2017:
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

12.07.2017: Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017

18.07.2017: Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

 

Oramed Announces Successful Meeting with FDA for Oral Insulin

http://www.nasdaq.com/press-release/...or-oral-insulin-20170905-00217

 

zur Hauptversammlung  

http://secfilings.nasdaq.com/...20INC.&FormType=8-K&View=html

 

Anstieg am Freitag !
Habe nur keine News gefunden.
Weiß jemand etwas ?  

Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

http://www.nasdaq.com/press-release/...h-with-its-oral-20171114-00613

 

http://secfilings.nasdaq.com/...0INC.&FormType=10-K&View=html

 

erst Q4 2019!?
Q4 ’19: Phase III study projected initiation (projected completion Q2 ’21) (Seite 4)  

dieser Thread scheint tot zu sein !?


Gibt die Aktie nichts mehr her ? Keine Perspektiven ?!